News Category: Uncategorized

CARLSBAD, Calif., February 28, 2019 – CarnoSyn^® Brands, a division of Natural Alternatives International, Inc. (“NAI”) (Nasdaq: NAII), and one of the world’s leading sports performance ingredients, has partnered with TEST Football Academy for the second year to provide NFL hopefuls with a scientifically-proven edge over the competition. This year, CarnoSyn^® Brands and TEST welcome Kaged Muscle^® to their team, working together to supplement the elite Combine training athletes with a full line of products containing daily doses of both CarnoSyn^® instant release and SR CarnoSyn^® sustained release beta-alanine.

“We are pleased to partner with TEST Football Academy and Kaged Muscle^® to help this year’s TEST Combine class attain peak performance,” said Nicole Burbank, Vice President of CarnoSyn^® Brands. “We are hopeful that many of the TEST athletes will end up playing professional football and are honored to contribute to the athlete’s success.”

In just 30 days, the TEST Combine class of 35 athletes has experienced incredible transformations, resulting in a total fat loss of 233 pounds and a total lean body mass (LBM) gain of 237 pounds—for a total body composition swing of 470 pounds. Per athlete, this averaged 6.7 pounds of fat loss and 6.8 pounds of LBM gain, with an average total swing of 13.5 pounds. In terms of performance increases, TEST athletes have achieved average increases of 2.5 inches on the vertical leap, 4 inches on the broad jump, 4 reps on the 225 bench press, and decreased 40 yard dash times by .15 seconds.

“Working with trusted partners like CarnoSyn^® and Kaged Muscle^®, who offer proven and banned substance-free products, solidifies the fact that we’re providing the best supplementation program available for our players,” explained Kevin Dunn, TEST Football Academy Owner and CEO. “We can argue all day on methodology and opinions, but the numbers provide undisputable evidence that this collective system truly works. We train the top 1% of athletes in the country, so incorporating sports performance ingredients like CarnoSyn^® and SR CarnoSyn^®, which are patented and supported by more than 55 scientific studies, is something that truly sets us apart from the competition. It allows our athletes to excel in all areas as they prep for a career in the NFL, CFL, AAF and soon to be XFL.”

Dunn went on to say, “This year has proven to be a landmark for TEST Football Academy, achieving some of the most mind blowing results in our 20-year history. Staying healthy and recovering optimally is no small task when training six days per week, two to three times per day. We elevated our game this year by enhancing our sports nutrition model with calorie and macro nutrient tracking and welcoming Kaged Muscle^® as our new sports nutrition partner. Kaged Muscle^® set the stage for us to dominate our workouts—Pre-Kaged®, In-Kaged^® and Re-Kaged^® was our go to stack in the weight room, providing the perfect combination of caffeine, creatine, and instant release CarnoSyn^® beta-alanine. Using this stack in conjunction with the SR CarnoSyn^® tablets helped regulate beta-alanine levels all day and packed a punch with lactic acid buffering when we needed it most. The results have been staggering, with an average of 6.7 pounds fat loss and 6.8 pounds of LBM gained. They arrived as boys… they left as men.”

Kaged Muscle^® CEO, Kris Gethin, stated, “There are numerous professional football players taking Kaged Muscle^® supplements, so it made sense to provide the same opportunity to pro football hopefuls and their coaches, which is why we decided to co-sponsor TEST Football with CarnoSyn^®, one of our patented ingredient manufacturers,” Gethin said. “CarnoSyn^® is a mainstay ingredient in our pre-workout, Pre-Kaged^®, our intra-workout, In-Kaged® and as a standalone sustained release version called SR CarnoSyn^®, which all help to buffer lactic acid and prolong endurance. Our supplements are some of the highest rated and reviewed products with standout fermented, patented and organic ingredients that are naturally flavored, naturally colored and banned substance free certified. Our products range from the highest premium protein isolates to the world’s first completely soluble creatine. Sports stars from the UFC to the Olympia stage choose Kaged Muscle^®, and now we are confident that football athletes will share this vision for their success too.”

As part of this partnership, CarnoSyn^® Brands is sponsoring three players from the 2019 TEST NFL Combine class and chronicling their inspirational journeys, primarily through video and social media, to build brand awareness and foster education on the efficacious loading and dosing of CarnoSyn^® and SR CarnoSyn^® beta-alanine. From NFL players to Olympians and legendary trainers, Team CarnoSyn^® is made up of athletes who will stop at nothing to achieve their dreams and who live by the mantra “Today I Will.”

Introducing the newest members of Team CarnoSyn®:

As pictured: Tuzar Skipper, Foster Moreau, Kevin Dunn, and Darnell Savage
Photo credit: Kyle Lieberman

Tuzar Skipper, Defensive End for Toledo Rockets
(Fat Loss – 3.7 pounds, LBM Gain – 12.6 pounds, Total Swing—16.3 pounds)
Skipper overcame adversity to earn a starting role on Toledo’s renowned defense and looks to use that opportunity to continue his pursuit of his NFL dream. He committed himself to dominate the training process and catapult himself to the next level, adding 12.6 pounds of LBM, becoming stronger, faster and more explosive than he’s ever been.

Foster Moreau, Tight End for Louisiana State University Tigers
(Fat Loss – 7.5 pounds, LBM Gain – 7.6 pounds, Total Swing—15.1 pounds)
After earning a reputation as a devastating blocker with consistently reliable hands in college football’s most elite conference, Moreau turned his sights to the 2019 Senior Bowl where he demonstrated a drive and dedication that earned him the prestigious South Team’s Player of the Week honors. The rigors of the NFL Combine will present Moreau with the opportunity to demonstrate his cerebral approach to the game of football, his precision footwork, and remarkable explosiveness.

Darnell Savage, Defensive Back for Maryland Terrapins
(Fat Loss – 2.4 pounds, LBM Gain – 10 pounds, Total Swing—12.4 pounds)
Savage was the physical and emotional leader of the 2018 Terrapins Football Team and led his squad through a season of triumph and tragedy, demonstrating veteran maturity both on and off the field. He carried that hard-hat work ethic with him to Mobile where he dominated a talented defensive back group to earn honors as the North Team’s Player of the Week. With the NFL Combine in his sights, Savage looks to demonstrate his near flawless technical abilities and world-class speed.

About CarnoSyn® Brands:
CarnoSyn^® Brands feature two clinically studied, patented ingredients available exclusively from Natural Alternatives International, Inc.: CarnoSyn^® instant release beta-alanine and SR CarnoSyn^® sustained release beta-alanine. In 2019, CarnoSyn^® beta-alanine successfully obtained NDI status from the FDA. In the sports nutrition segment, both ingredients are well known to deliver benefits for athletic performance: Increased strength, enhanced endurance, faster recovery and greater mental focus.

SR CarnoSyn^® is an advanced delivery form of CarnoSyn^®, which delivers higher dosing levels of beta-alanine, and is proven to provide benefits for both wellness and healthy aging. In 2017, SR CarnoSyn^® was determined to be safe through independent scientific procedures, thus satisfying the technical element of the Generally Recognized as Safe (GRAS) determination. The GRAS affirmation allows NAI to broaden their product offerings beyond the sports nutrition space and focus on the dietary supplement and food and beverage industries, including medical and other fortified food products.

About NAI:
NAI, headquartered in Carlsbad, California, is a leading formulator, manufacturer and marketer of nutritional supplements and provides strategic partnering services to its customers. NAI’s comprehensive partnership approach offers a wide range of innovative nutritional products and services to our clients including: scientific research, clinical studies, proprietary ingredients, customer-specific nutritional product formulation, product testing and evaluation, marketing management and support, packaging and delivery system design, regulatory review and international product registration assistance. For more information about NAI, please visit www.nai-online.com.

About TEST Football Academy:
TEST Football Academy has been training football players at all levels since 1999, marking 2019 as its 20th anniversary. Over that tenure, they have assembled the most experienced, world class team ever to prepare collegiate NFL prospects for the NFL Combine and Pro Days. They also work with youth and high school athletes, helping ballers of all ages get to the next level. This team of professionals consists of prominent performance coaches, international speed consultants, Super Bowl champions, pro bowlers, medical experts, sports psychologists, nutrition counselors, massage therapists, media personalities and interview prep professionals.

TEST Football Academy is the result of Owner and CEO, Kevin Dunn, Director of Football Operations, Geir Gudmundsen and a team professionals with over a century of collective experience, having worked with nearly 400 pro athlete hopefuls over two decades, with a success rate of over 250 athletes who have gone on to play professional football. They prepare athletes for the NFL Combine, Pro Days and help to extend NFL careers with consistent follow-up and coaching in the off season year after year. No longer does an athlete have to accept one trainer when they can have an entire team of experts supporting them on the most important journey of their lives with the potential to earn generational income.

About Kaged Muscle:
Kaged Muscle^® is an award winning, ultra-premium sports nutrition line and lifestyle brand, created to help athletes and fitness enthusiasts of all levels reach their transformation goals. Headquartered in Huntington Beach, California, KM is a rapidly growing producer of innovative, high-quality products in the sports nutrition category. Earning top accolades in 2017 and 2018 for their flagship products, Pre-Kaged^®, In-Kaged^® and Kasein^®, from sports nutrition retail giants Bodybuilding.com, GNC and Vitamin Shoppe, KM’s award-winning line has quickly become an industry leader for clean, premium quality products and the brand consumers can trust.

Formulated with research-backed premium quality and patented ingredients, each and every KM product undergoes rigorous in-lab development and testing as well as real-world use in the gym by top athletes, to ensure their quality and effectiveness. KM’s commitment to providing athletes of all levels with premium, safe, science-backed sports nutrition products sets the brand apart from many of its competitors. The comprehensive line of sports nutrition products is third party tested for purity and potency, contains no artificial colors or flavors, no synthetic caffeine, fermented and vegan-sourced amino acids, and is certified free of banned substances by Informed-Choice and Informed-Sport. In addition to offering premium quality products, KM also provides consumers with an array of powerful resources, including hundreds of articles, videos and online trainers, to help educate and guide them on their journey to better health and performance.

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934 that are not historical facts and information. These statements represent our intentions, expectations and beliefs concerning future events, including, among other things, our future revenue profits and financial condition, our ability to maintain our patents, generate revenues from the commercialization of our patents and trademarks, secure compliance with our intellectual property rights, and develop, maintain or increase sales to new and existing customers, as well as future economic conditions and the impact of such conditions on our business. We wish to caution readers that these statements involve risks and uncertainties that could cause actual results and outcomes for future periods to differ materially from any forward-looking statement or views expressed herein. NAI’s financial performance and the forward-looking statements contained herein are further qualified by other risks, including those set forth from time to time in the documents filed by us with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K.

CONTACT:
Renee Michaelson, CarnoSyn^® Marketing Manager, Natural Alternatives International, Inc., at 760-736-7700 or [email protected].
Websites: http://team.carnosyn.com/ and http://www.srcarnosyn.com/ and http://nai-online.com

SOURCE: Natural Alternatives International, Inc.

CARLSBAD, Calif., Feb. 19, 2019 /PRNewswire/ — Natural Alternatives International, Inc. (“NAI”) (NASDAQ: NAII), a leading formulator, and marketer of customized nutritional supplements proudly announced today that it has received New Dietary Ingredient (NDI) status from the Food and Drug Administration (FDA) for its patented CarnoSyn^® beta-alanine ingredient at a total daily intake level of 6.4 grams per day.  NAI received the FDA’s Acknowledgement Without Objection or AKL letter within its statutory 75-day evaluation period to respond. It has been assigned NDI report number 1103. CarnoSyn^® is the only beta-alanine that has successfully obtained NDI status with the FDA.

The Federal Food, Drug, and Cosmetic Act (FD&C Act) requires that manufacturers and distributors who wish to market dietary supplements that contain “new dietary ingredients” notify the FDA about these ingredients. Generally, the notification must include information that is the basis on which the manufacturer or distributor has concluded that a dietary supplement containing a new dietary ingredient will reasonably be expected to be safe under the conditions of use recommended or suggested in the labeling. (See Section 413(d) of the FD&C Act, 21 U.S.C. 350b(d)).

CarnoSyn^® beta-alanine is widely-recognized as a patented, high-quality ingredient of choice among companies wishing to use the safest ingredients in their products. NAI has invested millions of dollars of research into CarnoSyn^® beta-alanine over the years and developed a robust portfolio of patents and trademarks to protect its proprietary rights. With the additional exclusivity an NDI notification affords NAI, it will be working diligently with the FDA, CBP, FTC and various other federal and state agencies to ensure compliance and safety by those companies using beta-alanine. Where companies continue to buy and use generic beta-alanine not covered by its NDI, NAI will be alerting the necessary agencies of non-compliance. To the extent such unfair practices also include any infringement of NAI’s intellectual property, these violations will be vigorously pursued.

Mark A. LeDoux, NAI’s CEO and Chairman of the Board, expressed his enthusiasm at obtaining NDI status for CarnoSyn^® beta-alanine. “CarnoSyn^® is recognized as a leading ingredient, backed by a body of science and intellectual property. The FDA’s acknowledgement of our NDI notification demonstrates not only the safety of CarnoSyn^®, but also NAI’s long-standing commitment to regulatory compliance. Dr. Gottlieb, the head of the FDA, and the Office of Dietary Supplements have demonstrated that they take the safety of dietary supplements seriously. So does NAI. We intend to work hand-in-hand with the FDA and other agencies or courts to zealously advocate for the use of safe ingredients, demonstrated through compliance with the New Dietary Ingredient process, protection of intellectual property and increased investment in research and development. We applaud the licensees of CarnoSyn^® for their recognition of the safety, benefits and IP related to our product. For those entities who continue to conceal themselves in darkness from regulatory and IP compliance, NAI will not silently stand by, but rather will soon be providing a list of companies to the FDA using adulterated beta-alanine. The time is now for those who went through the rigors of properly obtaining NDIs and intellectual property to forcefully lead and direct the industry into increased compliance and ensure the safety of products sold to consumers.”

LeDoux, who is also the current Chairman of the Natural Products Association, said that the FDA’s February 11, 2019, announcement regarding dietary supplements “is welcomed by industry and those companies who invest in safety and compliance of their products. Director Gottlieb’s stated commitment to greater enforcement of NDIs further assures companies like NAI that their investment in regulatory compliance and enforcement efforts will be taken seriously. NAI intends to continue leading by example.”

NAI, headquartered in Carlsbad, California, is a leading formulator, manufacturer and marketer of nutritional supplements and provides strategic partnering services to its customers. NAI’s comprehensive partnership approach offers a wide range of innovative nutritional products and services to NAI’s clients including: scientific research, clinical studies, proprietary ingredients, customer-specific nutritional product formulation, product testing and evaluation, marketing management and support, packaging and delivery system design, regulatory review and international product registration assistance. For more information about NAI, please see its website at http://nai-online.com.

This press release contains forward-looking statements within the meaning of applicable securities laws that are not historical facts and information. These statements represent our intentions, expectations and beliefs concerning future events, including, among other things, our expectations and beliefs with respect to our future financial and operating results, the outcome of pending litigation, the continued validity of our patents, and our ability to successfully develop, license and enforce our intellectual property rights. We wish to caution readers these statements involve risks and uncertainties that could cause actual results and outcomes for future periods to differ materially from any forward-looking statement or views expressed herein. NAI’s financial performance and the forward-looking statements contained herein are further qualified by other risks including those set forth from time to time in the documents filed by us with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q.

CONTACT – Kenneth Wolf, President and Chief Operating Officer, Natural Alternatives International, Inc., at 760-736-7700 or [email protected].

SOURCE Natural Alternatives International, Inc.
Related Links
http://nai-online.com

– Q2 fiscal 2019 Net Sales increase 8% – Pre-Tax Income increases 11%
– YTD fiscal 2019 Net Sales increase 18% – Pre-Tax Income increases 33%

CARLSBAD, Calif., Feb. 12, 2019 /PRNewswire/ — Natural Alternatives International, Inc. (“NAI”) (Nasdaq: NAII), a leading formulator, manufacturer and marketer of customized nutritional supplements, today announced net income of $2.2 million, or $0.31 per diluted share, on net sales of $36.0 million for the quarter ended December 31, 2018.

Net income for our second quarter of fiscal 2019 was $2.2 million, or $0.31 per diluted share, compared to a net loss of $1.3 million, or ($0.20) per diluted share, in the second quarter of fiscal 2018. Excluding second quarter 2018 discrete tax items, our adjusted net income was $1.9 million, or $0.29 per diluted share. The second quarter of fiscal 2018 results were unfavorably impacted by one-time discrete tax expense amounts recorded in connection with the Tax Cuts and Jobs Act (the “Tax Act”). These one-time charges totaled $3.3 million, or approximately $0.49 per diluted share.

Net sales during the three months ended December 31, 2018 increased $2.7 million, or 8.1%, from $33.3 million recorded in the comparable prior year period. For the quarter ended December 31, 2018, private label contract manufacturing sales increased $2.3 million, or 7.9%, from the comparable quarter last year. Second quarter contract manufacturing sales increased primarily due to the sale of new products to new and existing customers and higher volumes of current products to existing customers.

CarnoSyn^® beta-alanine royalty, licensing and raw material sales revenue increased 10.1% to $4.4 million during the second quarter of fiscal 2019, as compared to $4.0 million for the second quarter of fiscal 2018. The increase in CarnoSyn® revenue was primarily due to higher sales volumes to existing customers partially offset by lower average material sales prices.

Net income for the six months ended December 31, 2018 was $4.7 million, or $0.68 per diluted share, compared to net income of $0.1 million, or $0.02 per diluted share, for the six months ended December 31, 2017. Excluding discrete tax items, our adjusted net income during the six months ended December 31, 2017 was $3.4 million, or $0.50 per diluted share. The previous period’s results were unfavorably impacted by one-time discrete tax expense amounts recorded in connection with the Tax Act. These one-time charges totaled $3.3 million, or approximately $0.48 per diluted share.

Net sales during the six months ended December 31, 2018 increased $11.2 million, or 18.2%, from $61.4 million recorded in the comparable prior year period. For the six months ended December 31, 2018, private label contract manufacturing sales increased $11.2 million, or 21.7%, from the comparable period last year. Second quarter contract manufacturing sales increased primarily due to the sale of new products to new and existing customers and higher volumes of current products to existing customers.

CarnoSyn^® beta-alanine royalty, licensing and raw material sales revenue during the first six months of fiscal 2019 were $9.8 million which was consistent with the first six months of fiscal 2018.

As of December 31, 2018, we had cash of $30.3 million and working capital of $56.5 million compared to $23.6 million and $50.9 million, respectively, as of June 30, 2018. As of December 31, 2018, we had $10.0 million available under our line of credit agreement.

Mark A. LeDoux, Chairman and Chief Executive Officer stated, “We continue to see market expansion for our products, both in the CarnoSyn^® arena and in contract manufacturing. With our commitment to quality and dedication to exceeding our customers’ expectations, the continued course of action remains bright. Due to increased demands in different markets, we are continuing to expand our manufacturing capabilities in Switzerland, while simultaneously updating operational efficiencies in our California facilities.”

“I am very grateful to the NAI team members who demonstrate excellence in their everyday efforts, as exemplified by these financial results. As we endeavor to grow our existing business we continue to evaluate potential opportunities for accretive transactions that could further expand our footprint in this exciting industry, while continuing to invest in the scientific research and regulatory compliance efforts which have set us apart from others unable or unwilling to do so.”

Reconciliation of Non-GAAP Information

The GAAP results contained in this press release and the financial statement schedules attached to this press release have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”). In addition to the Company’s results prepared in accordance with GAAP, the Company provided information on a non-GAAP basis. The manner in which this non-GAAP information is derived is discussed below, and the Company has provided in the tables to this release a reconciliation of the non-GAAP information to the most directly comparable GAAP information.

Net Income (Loss) and EPS Adjusted for Non-Recurring Tax Expense. In order to make the fiscal year 2017 results comparable to fiscal year 2018, we have presented net income and EPS for the three and six months ended December 31, 2017 on a non-GAAP basis by excluding discrete tax items of $3.3 million related to the Tax Act for both the three and six month periods. The following is schedule reconciling our Adjusted Net Income (Loss) and EPS to our GAAP Net Income (Loss) and EPS.

NAI, headquartered in Carlsbad, California, is a leading formulator, manufacturer and marketer of nutritional supplements and provides strategic partnering services to its customers. Our comprehensive partnership approach offers a wide range of innovative nutritional products and services to our clients including: scientific research, clinical studies, proprietary ingredients, customer-specific nutritional product formulation, product testing and evaluation, marketing management and support, packaging and delivery system design, regulatory review and international product registration assistance. For more information about NAI, please see our website at http://nai-online.com.

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934 that are not historical facts and information. These statements represent our intentions, expectations and beliefs concerning future events, including, among other things, future acquisitions, revenue profits and financial condition, our ability to maintain our patents, generate revenues from the commercialization of our patents and trademarks, secure compliance with our intellectual property rights, and develop, maintain or increase sales to new and existing customers, as well as future economic conditions and the impact of such conditions on our business. We wish to caution readers that these statements involve risks and uncertainties that could cause actual results and outcomes for future periods to differ materially from any forward-looking statement or views expressed herein. NAI’s financial performance and the forward-looking statements contained herein are further qualified by other risks, including those set forth from time to time in the documents filed by us with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K.

CONTACT – Michael Fortin, Chief Financial Officer, Natural Alternatives International, Inc., at 760-736-7700 or [email protected].

Web site: http://nai-online.com

Cision View original content:http://www.prnewswire.com/news-releases/natural-alternatives-international-inc-announces-2019-q2-and-ytd-results-300794351.html

SOURCE Natural Alternatives International, Inc.

CARLSBAD, Calif., Jan. 23, 2019 /PRNewswire/ — Natural Alternatives International, Inc. (“NAI”) (Nasdaq: NAII) today announced its participation in the 15th edition of the Integrative Healthcare Symposium, the only event where multi-disciplinary practitioners come together as a cohesive community to learn and collaborate on insights and techniques related to the cutting edge of holistic healthcare. This three-day event will be held on February 21-23, 2019, at the New York Hilton in Midtown, New York.

In late 2018, NAI launched their healthy aging & wellness expansion with SR CarnoSyn^® beta-alanine, a patented, sustained release form of beta-alanine, which combines naturally with histidine in the body to produce carnosine. A powerful natural antioxidant, carnosine has been rigorously researched and clinically proven to provide support for muscle, cognitive and systemic function.

“Our attendance at the Integrative HealthCare Symposium underscores our commitment to the healthcare practitioner market and providing professional education regarding the myriad of health benefits that can be derived by supplementing with beta-alanine,” stated Nicole Burbank, CarnoSyn^® Brands Vice President.

NAI will showcase SR CarnoSyn^® for everyday wellness and healthy aging at booth TT9 and is sponsoring a Lunch & Learn with Dr. Jay Hoffman on Friday, February 22, from 12:00 PM – 1:30 PM, in the Morgan Suite. The session, “How Beta-Alanine Supplementation Supports Healthy Aging via Supporting Cognitive Function and Muscle Health,” will focus on the scientific studies regarding beta-alanine supplementation and its role in generating carnosine in the body to support overall systemic health, cognitive function and muscle support. The efficacy of the patented delivery system of beta-alanine as SR CarnoSyn^® will also be presented.

Session Learning Objectives:

Participants will be able to explain how beta-alanine supplementation can lead to support of cognitive function to benefit healthy aging and wellness.
Participants will be able to explain the best delivery form of beta-alanine to increase carnosine content in tissue.
Participants will be able to discuss the efficacy of beta-alanine ingestion on maximizing physical performance in different age and training groups, including competitive and tactical athletic populations.

About Jay Hoffman Ph.D., FNSCA, FACSM:
Dr. Hoffman holds the rank of full professor in the Sport and Exercise Science program and Professor of Medicine at the Burnett School of Biomedical Sciences at the University of Central Florida. Previously he served as President of the Board of the National Strength and Conditioning Association (NSCA) from 2009-2012. Dr. Hoffman has also served on the Board of the USA Bobsled and Skeleton Federation. Dr. Hoffman holds a unique perspective in his sport science background.

As a sport scientist, Dr. Hoffman has published more than 300 articles and chapters in peer-reviewed journals and 8 books. In addition, Dr. Hoffman has lectured at more than 500 national and international conferences and meetings. Dr. Hoffman has also been honored with the 2007 Outstanding Sport Scientist of the Year from the NSCA and 2005 Outstanding Kinesiology Professional Award from the Neag School of Education of the University of Connecticut. Dr. Hoffman’s research efforts have focused on examining nutrient intervention for increasing resiliency or enhancing recovery from various stresses. In addition, recent research interests also involve nutrient intervention for healthy aging.

For more information and to register for the Integrative Healthcare Symposium, please visit www.ihsymposium.com.

About CarnoSyn® Brands:
CarnoSyn^® Brands feature two clinically studied, patented ingredients available exclusively from Natural Alternatives International, Inc.: CarnoSyn^® instant release beta-alanine and SR CarnoSyn^® sustained release beta-alanine. In the sports nutrition segment, both ingredients are well known to deliver benefits for athletic performance: Increased strength, enhanced endurance, faster recovery, and greater mental focus.

SR CarnoSyn^® is an advanced delivery form of CarnoSyn^®, which delivers higher dosing levels of beta-alanine, and is proven to provide benefits for both wellness and healthy aging. In 2017, SR CarnoSyn^® was determined to be safe through independent scientific procedures, thus satisfying the technical element of the Generally Recognized as Safe (GRAS) determination. The GRAS affirmation allows NAI to broaden their product offerings beyond the sports nutrition space and focus on the dietary supplement and food and beverage industries, including medical and other fortified food products.

About NAI:
NAI, headquartered in Carlsbad, California, is a leading formulator, manufacturer and marketer of nutritional supplements and provides strategic partnering services to its customers. NAI’s comprehensive partnership approach offers a wide range of innovative nutritional products and services to our clients including: scientific research, clinical studies, proprietary ingredients, customer-specific nutritional product formulation, product testing and evaluation, marketing management and support, packaging and delivery system design, regulatory review and international product registration assistance. For more information about NAI, please visit www.nai-online.com.

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934 that are not historical facts and information. These statements represent our intentions, expectations and beliefs concerning future events, including, among other things, our future revenue profits and financial condition, our ability to maintain our patents, generate revenues from the commercialization of our patents and trademarks, secure compliance with our intellectual property rights, and develop, maintain or increase sales to new and existing customers, as well as future economic conditions and the impact of such conditions on our business. We wish to caution readers that these statements involve risks and uncertainties that could cause actual results and outcomes for future periods to differ materially from any forward-looking statement or views expressed herein. NAI’s financial performance and the forward-looking statements contained herein are further qualified by other risks, including those set forth from time to time in the documents filed by us with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K.

CONTACT:
Renee Michaelson, CarnoSyn^® Marketing Manager, Natural Alternatives International, Inc., at 760-736-7700 or [email protected].
Websites: http://www.srcarnosyn.com/ and http://www.carnosyn.com and http://nai-online.com

Cision View original content:http://www.prnewswire.com/news-releases/natural-alternatives-international-announces-participation-as-exhibitor-and-sponsor-in-the-2019-integrative-healthcare-symposium-300783049.html

SOURCE Natural Alternatives International, Inc.

– Net Sales increase 30% compared to the first quarter of the prior year
– Net Income and EPS increase over 75% compared to the first quarter of the prior year

CARLSBAD, Calif., Nov. 13, 2018 /PRNewswire/ — Natural Alternatives International, Inc. (“NAI”) (Nasdaq: NAII), a leading formulator, manufacturer and marketer of customized nutritional supplements, today announced net income of $2.6 million, or $0.37 per diluted share, on net sales of $36.5 million for the quarter ended September 30, 2018

Net sales during the three months ended September 30, 2018 increased $8.5 million, or 30.1%, from $28.1 million recorded in the comparable prior year period. For the quarter ended September 30, 2018, private label contract manufacturing sales increased $8.9 million, or 39.9%, from the comparable quarter last year. First quarter contract manufacturing sales increased primarily due to the sale of new products to existing customers and higher volumes of current products to existing customers. The increase in sales included shipment of new products and increased sales of existing products to our largest customer under our previously announced expanded relationship.

CarnoSyn^® beta-alanine royalty, licensing and raw material sales revenue decreased 6.9% to $5.4 million during the first quarter of fiscal 2019, as compared to $5.9 million for the first quarter of fiscal 2018. The decrease in CarnoSyn^® revenue was primarily due to lower average material sales prices.

Net income for our first quarter of fiscal 2019 was $2.6 million, or $0.37 per diluted share, compared to net income of $1.4 million, or $0.21 per diluted share, in the first quarter of fiscal 2018. The increase in net income is primarily due to increased private label contract manufacturing sales, favorable interest income associated with our foreign currency hedging program, and a lower effective tax rate associated with the Tax Cuts and Jobs Act enacted in December 2017.

As of September 30, 2018, NAI had cash of $27.6 million and working capital of $54.5 million compared to $23.6 million and $50.9 million, respectively, as of June 30, 2018. As of September 30, 2018, we had $10.0 million available under our line of credit agreement.

Mark A. Le Doux, Chairman and Chief Executive Officer stated, “As anticipated, we have experienced growth in existing markets and are beginning to see new revenue sources from new customers to complement our core customers. More and more companies recognize the true value-add that NAI brings as a manufacturing partner, not only in production of dietary supplements, but in applying the discipline of sound research in formulating, applying rigorous standards in product and pilot development, and using our many years of experience in sourcing the finest ingredients to deploy for our customers, assuring quality and consistency.”

“We have added seasoned personnel with great reputations into our business at a variety of levels, and are excited at the prospects for entering new channels of commerce with our robust intellectual property estate surrounding sustained release CarnoSyn^® beta-alanine. We continue to provide leadership for the natural products industry by continuing to advance the efforts of the Supplement Safety Compliance Initiative, which seeks to solidify consumer trust in our products and which is led by major retailers with huge footprints in this industry, while also serving the members of the Natural Products Association in Washington D.C. at the Board of Director level. With the latest election results, there will be much opportunity for discussion as we seek to educate the newest members of Congress on the virtues of preventive approaches to disease development, and the significant benefit to the nation in terms of reduction of cost to the health care system and the taxpayer.”

NAI, headquartered in Carlsbad, California, is a leading formulator, manufacturer and marketer of nutritional supplements and provides strategic partnering services to its customers. Our comprehensive partnership approach offers a wide range of innovative nutritional products and services to our clients including: scientific research, clinical studies, proprietary ingredients, customer-specific nutritional product formulation, product testing and evaluation, marketing management and support, packaging and delivery system design, regulatory review and international product registration assistance. For more information about NAI, please see our website at http://nai-online.com.

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934 that are not historical facts and information. These statements represent our intentions, expectations and beliefs concerning future events, including, among other things, our future revenue profits and financial condition, our ability to maintain our patents, generate revenues from the commercialization of our patents and trademarks, secure compliance with our intellectual property rights, and develop, maintain or increase sales to new and existing customers, as well as future economic conditions and the impact of such conditions on our business. We wish to caution readers that these statements involve risks and uncertainties that could cause actual results and outcomes for future periods to differ materially from any forward-looking statement or views expressed herein. NAI’s financial performance and the forward-looking statements contained herein are further qualified by other risks, including those set forth from time to time in the documents filed by us with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K.

CONTACT – Michael Fortin, Chief Financial Officer, Natural Alternatives International, Inc., at 760-736-7700 or [email protected].

Web site: http://nai-online.com

Cision View original content:http://www.prnewswire.com/news-releases/natural-alternatives-international-inc-announces-2019-q1-results-300749588.html
SOURCE Natural Alternatives International, Inc.

CARLSBAD, Calif., Nov. 5, 2018 /PRNewswire/ — Natural Alternatives International, Inc. (“NAI”) (Nasdaq: NAII) is pleased to announce the launch of a new website to promote the SR CarnoSyn^® beta-alanine market expansion into the healthy aging and general wellness markets. The newly designed website offers insightful information on the top five health benefits of SR CarnoSyn^®, research, product formats, FAQs and contact information.

NAI will debut the healthy aging & wellness expansion at SupplySide West in Las Vegas, November 8-9, 2018. Dr. Jay Hoffman will be a featured guest at NAI’s booth #4933 on November 8th, from 10:00 am – 12:00 pm, and will be available to speak to industry contacts who are seeking to learn more about the latest advances with SR CarnoSyn^® in the general wellness and healthy aging.

“We are excited about our new website launch and supporting sales collateral,” stated Nicole Burbank, CarnoSyn^® Brands Vice President. “NAI is aggressively pursuing partnerships with key players in the general wellness and healthy aging markets to provide unique SR CarnoSyn^® product offerings to the supplement and specialty food categories. SupplySide West will provide a good starting point for this endeavor.”

The new website has a clean, modern design and will allow visitors to have a very informative experience as the brand continues to grow and increase market presence. NAI invites visitors to explore the website and to sign up for direct emails from the company at www.srcarnosyn.com.

About CarnoSyn® Brands:
CarnoSyn^® Brands feature two clinically studied, patented ingredients available exclusively from Natural Alternatives International, Inc.: CarnoSyn^® instant release beta-alanine and SR CarnoSyn^® sustained release beta-alanine. In the sports nutrition segment, both ingredients are well known to deliver benefits for athletic performance: Increased strength, enhanced endurance, faster recovery, and greater mental focus.

SR CarnoSyn^® is an advanced delivery form of CarnoSyn^®, which delivers higher dosing levels of beta-alanine, and is proven to provide benefits for both brain health and muscle function and capacity. In 2017, SR CarnoSyn^® was determined to be safe through independent scientific procedures, thus satisfying the technical element of the Generally Recognized as Safe (GRAS) determination. The GRAS affirmation allows NAI to broaden their product offerings beyond the sports nutrition space and focus on the dietary supplement and food and beverage industries, including medical and other fortified food products.

CarnoSyn^® and SR CarnoSyn^® are ultra-pure amino acids and banned substance free, backed by NAI’s commitment to the highest quality, potency, and manufacturing standards. For more information about CarnoSyn^® and SR CarnoSyn^®, please visit www.carnosyn.com and www.srcarnosyn.com.

About NAI:
NAI, headquartered in Carlsbad, California, is a leading formulator, manufacturer and marketer of nutritional supplements and provides strategic partnering services to its customers. NAI’s comprehensive partnership approach offers a wide range of innovative nutritional products and services to our clients including: scientific research, clinical studies, proprietary ingredients, customer-specific nutritional product formulation, product testing and evaluation, marketing management and support, packaging and delivery system design, regulatory review and international product registration assistance. For more information about NAI, please visit www.nai-online.com.

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934 that are not historical facts and information. These statements represent our intentions, expectations and beliefs concerning future events, including, among other things, our future revenue profits and financial condition, our ability to maintain our patents, generate revenues from the commercialization of our patents and trademarks, secure compliance with our intellectual property rights, and develop, maintain or increase sales to new and existing customers, as well as future economic conditions and the impact of such conditions on our business. We wish to caution readers that these statements involve risks and uncertainties that could cause actual results and outcomes for future periods to differ materially from any forward-looking statement or views expressed herein. NAI’s financial performance and the forward-looking statements contained herein are further qualified by other risks, including those set forth from time to time in the documents filed by us with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K.

CONTACT:
Renee Michaelson, CarnoSyn^® Marketing Manager, Natural Alternatives International, Inc., at 760-736-7700 or [email protected].
Website: http://www.carnosyn.com and http://nai-online.com

Cision View original content:http://www.prnewswire.com/news-releases/natural-alternatives-international-announces-new-website-launch-to-support-market-expansion-initiative-into-healthy-aging–everyday-wellness-300744057.html

SOURCE Natural Alternatives International, Inc.

– Fourth quarter fiscal 2018 Net Sales increase 22% compared to the fourth quarter of fiscal 2017
– Fourth quarter fiscal 2018 Net Income and EPS increase over 80% compared to the fourth quarter of fiscal 2017

CARLSBAD, Calif., Sept. 19, 2018 /PRNewswire/ — Natural Alternatives International, Inc. (“NAI”) (Nasdaq: NAII), a leading formulator, manufacturer and marketer of customized nutritional supplements, today announced net income of $2.9 million, or $0.41 per diluted share, on net sales of $39.2 million for the quarter ended June 30, 2018. This represents an increase of $0.18 per diluted share as compared to the same quarter in fiscal 2017 and was primarily attributable to increased private label contract manufacturing sales, reduced legal expenses associated with our CarnoSyn^® beta-alanine business, and favorable other income associated with our foreign currency hedging program, partially offset by lower CarnoSyn^® beta-alanine sales. Quarterly results were also favorably impacted by one-time tax amounts recorded in connection with revisions to our estimates associated with the Tax Cuts and Jobs Act (the “Act”) that was enacted on December 22, 2017. These one-time adjustments totaled $0.2 million, or approximately $0.03 per diluted share. Excluding these one-time tax items, our adjusted net income during the fourth quarter of fiscal 2018 was $2.7 million, or $0.38 per diluted share.

Net sales during the three months ended June 30, 2018 increased $7.0 million, or 21.8%, from $32.2 million recorded in the comparable prior year period. For the quarter ended June 30, 2018, private label contract manufacturing sales increased $8.5 million, or 33.8%, from the comparable quarter last year. Fourth quarter contract manufacturing sales increased primarily due to sales to Asian and European markets returning to historical levels and an increase in sales to our largest customer, including shipment of new products under our previously announced expanded relationship.

CarnoSyn^® beta-alanine royalty, licensing and raw material sales revenue decreased 21.6% to $5.4 million during the fourth quarter of fiscal 2018 as compared to $6.9 million for the fourth quarter of fiscal 2017. The decrease in CarnoSyn^® revenue was primarily due to decreased beta-alanine shipments as a result of market and seasonal factors and lower average beta-alanine sales prices.

Net sales during fiscal 2018 increased $10.5 million to $132.4 million, or 8.6%, from $121.9 million recorded in the comparable prior year period. Fiscal 2018 private label contract manufacturing net sales increased $16.0 million, or 16.8%, from the comparable period last year. The increase was primarily related to the sale of new products to existing customers and higher volumes of current products to existing customers located primarily in U.S., Asian, and European markets. These increases were partially offset by discontinued U.S. customer relationships. The increase in sales included shipment of new products and increased sales of existing products to our largest customer under our previously announced expanded relationship.

CarnoSyn^® beta-alanine royalty, licensing and raw material sales revenue decreased 20.3% to $21.4 million during fiscal 2018 as compared to $26.9 million for fiscal 2017. The decrease in CarnoSyn^® revenue was primarily due to decreased beta-alanine shipments as a result of market and seasonal factors and lower average beta-alanine sales prices. During the quarter ended December 31, 2017, sports nutrition retail market conditions declined most notably in the older “brick and mortar” sales channels as products transitioned to higher levels of internet based sales. This transition resulted in excess inventory in certain channels and delayed the re-order rates for many of our customer brands. Additionally, while we still have active patents covering instant release CarnoSyn^® beta-alanine, we experienced increased competition from companies selling generic beta-alanine beginning in the second quarter of fiscal 2018, resulting in certain customers discontinuing the use of our CarnoSyn^® beta-alanine. To offset this decline, and in addition to legal actions we have prosecuted and others we may institute, we have increased our sales and marketing activities to consumers, customers, potential customers, and brand owners on multiple platforms to promote and reinforce the features and benefits of utilizing CarnoSyn^® beta-alanine. During the second half of fiscal 2018, our re-order rates improved and reached near historical levels, suggesting to us both improved sports nutrition retail market conditions and potentially a positive impact from our marketing activities. Additionally, our SR CarnoSyn^® product and raw material sales continued to rise as more brands adopted product offerings of this sustained release delivery system. There can be no assurance our sales and marketing efforts or the recent apparent improvement in retail market conditions will continue.

Net income for fiscal 2018 was $5.1 million, or $0.73 per diluted share, compared to net income of $7.2 million, or $1.09 per diluted share, in the comparable prior year period. Our 2018 results were unfavorably impacted by one-time tax expenses recorded in connection with the revised U.S. tax code. These one-time charges totaled $3.0 million, or approximately $0.44 per diluted share. Excluding these one-time tax items, our adjusted net income during fiscal 2018 was $8.1 million, or $1.17 per diluted share. The increase in net income adjusted for one-time tax adjustments is primarily due to increased private label contract manufacturing net sales, favorable other income associated with our foreign currency hedging program, and a lower effective tax rate associated with the tax reform, partially offset by decreased CarnoSyn^® beta-alanine sales.

As of June 30, 2018, NAI had cash of $23.6 million and working capital of $50.9 million compared to $27.8 million and $41.4 million, respectively, as of June 30, 2017. As of June 30, 2018, we had $10.0 million available under our line of credit agreement.

Mark A. Le Doux, Chairman and Chief Executive Officer stated, “Fiscal Year 2018 was a record year in sales for NAI. As we enter fiscal 2019, we are planning for continued growth in our existing markets and anticipate new revenue sources as we expand our footprint in the natural products industry. We are forecasting growth with current relationships and a continued expansion of our client base with an emphasis on high-quality consumer products delivering exceptional value.”

“We continue adding talented people into our businesses, with the experience and gravitas to expand our CarnoSyn^® Brands reach into the wellness markets, the health care practitioner space, clinics and other sales channels, while continuing to find ways to innovate based on sound science and ethical business principles.”

“Our solid financial strength and ability to generate significant cash flow should provide us ample opportunities to facilitate our growth objectives in fiscal 2019 and beyond. I am deeply grateful to my team of professionals for their continued dedication and focus, helping us reach new heights in sales and profitability as we seek to enrich the world through the best of nutrition.”

NAI, headquartered in Carlsbad, California, is a leading formulator, manufacturer and marketer of nutritional supplements and provides strategic partnering services to its customers. Our comprehensive partnership approach offers a wide range of innovative nutritional products and services to our clients including: scientific research, clinical studies, proprietary ingredients, customer-specific nutritional product formulation, product testing and evaluation, marketing management and support, packaging and delivery system design, regulatory review and international product registration assistance. For more information about NAI, please see our website at http://nai-online.com.

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934 that are not historical facts and information. These statements represent our intentions, expectations and beliefs concerning future events, including, among other things, our future revenue profits and financial condition, our ability to maintain our patents, generate revenues from the commercialization of our patents and trademarks, secure compliance with our intellectual property rights, and develop, maintain or increase sales to new and existing customers, as well as future economic conditions and the impact of such conditions on our business. We wish to caution readers that these statements involve risks and uncertainties that could cause actual results and outcomes for future periods to differ materially from any forward-looking statement or views expressed herein. NAI’s financial performance and the forward-looking statements contained herein are further qualified by other risks including those set forth from time to time in the documents filed by us with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K.

CONTACT – Michael Fortin, Chief Financial Officer, Natural Alternatives International, Inc., at 760-736-7700 or [email protected].

Web site: http://nai-online.com

Cision View original content:http://www.prnewswire.com/news-releases/natural-alternatives-international-inc-announces-fiscal-2018-and-q4-results-300715580.html

SOURCE Natural Alternatives International, Inc.

CARLSBAD, Calif., May 14, 2018 /PRNewswire/ — Natural Alternatives International, Inc. (“NAI”) (Nasdaq: NAII), a leading formulator, manufacturer and marketer of customized nutritional supplements, today announced net income of $2.1 million, or $0.30 per diluted share, on net sales of $31.8 million for the quarter ended March 31, 2018.

Net income for the third quarter of fiscal 2018 was $2.1 million, or $0.30 per diluted share, compared to net income of $0.7 million, or $0.11 per diluted share, in the comparable prior year period.  This increase was primarily attributable to growth in net sales associated with our private label contract manufacturing business.

Net sales during the three months ended March 31, 2018 increased $6.7 million, or 26.6%, from $25.1 million recorded in the comparable prior year period.  For the quarter ended March 31, 2018, private label contract manufacturing sales increased $7.1 million, or 38.3%, from the comparable quarter last year. Third quarter contract manufacturing sales increased primarily due to sales to Asian and European markets returning to historical levels and an increase in sales to our largest customer including shipment of new products under our previously announced expanded relationship.

CarnoSyn® beta-alanine royalty, licensing and raw material sales revenue decreased 6.4% to $6.2 million during the third quarter of fiscal 2018 as compared to $6.6 million for the third quarter of fiscal 2017.  On a trailing quarter basis, CarnoSyn® beta-alanine royalty, licensing and raw material sales increased 55.0%, or $2.2 million, during the third quarter of fiscal 2018 as compared to the second quarter of fiscal 2018.  During our third quarter ending March 31, 2018, re-order rates improved for many of our customer brands. Additionally, our SR CarnoSyn® raw material sales continued to increase during the third quarter of fiscal 2018 as more brands adopted product offerings using our proprietary and effective sustained release delivery system.

Net sales during the nine months ended March 31, 2018 increased $3.5 million to $93.2 million, or 3.9%, from $89.8 million recorded in the comparable prior year period.  For the nine months ended March 31, 2018, private label contract manufacturing sales increased $7.4 million, or 10.7%, from the comparable period last year. The increase was primarily due to higher volumes of current products to existing customers located in Asian and European markets and shipment of new products under our previously announced expanded relationship with our largest customer.

CarnoSyn® beta-alanine royalty, licensing and raw material sales revenue decreased 19.9% to $16.0 million during the first nine months of fiscal 2018 as compared to $20.0 million for the comparable prior year period.

Net income for the first nine months of fiscal 2018 was $2.2 million, or $0.32 per diluted share, compared to net income of $5.7 million, or $0.86 per diluted share, in the comparable prior year period. Our year-to-date fiscal 2018 results were unfavorably impacted by one-time tax expense recorded in connection with the revised U.S. tax code.  These one-time charges totaled $3.3 million, or approximately $0.47 per diluted share.  Excluding these one-time tax items, our adjusted net income during the first nine months of fiscal 2018 was $5.4 million, or $0.79 per diluted share.  Other than the one time tax expense the decrease in adjusted net income was primarily attributable to increased selling, general & administrative expenses from our patent and trademark licensing segment and increased marketing, advertising, and research and development costs supporting our CarnoSyn® and SR CarnoSyn® brands. These cost increases were partially offset by a reduction in patent litigation costs and increased gross profit from increased sales.

As of March 31, 2018, NAI had cash of $27.6 million and working capital of $45.3 million compared to $27.8 million and $41.4 million, respectively, as of June 30, 2017.  As of March 31, 2018, we had $10.0 million available under our line of credit agreement.

Mark A. Le Doux, Chairman and Chief Executive Officer stated, “Our investment in the expansion of market awareness of CarnoSyn® in addition to our commitment to ongoing research has born the anticipated positive results with a return to a more normal level of sales for this remarkable product. The recent success of our ‘team’ of supported athletes with four of the five sponsored athletes developing relationships with NFL teams during the NFL Draft demonstrates the intrinsic value of the correct supplementation of CarnoSyn®. The enhanced performance metrics achieved with this safe and legal supplement speaks volumes to athletes of all ages and aspirations.

“Equally gratifying was the growth experienced in our custom contract manufacturing business both in the US and in Switzerland. Continued expansion of customer needs in Australasia, Europe and North America have engendered revenue growth.  We expect this trend to continue with the normal potential for some seasonality to emerge in later periods. The larger progression we believe is occurring in our industry is a shift by quality conscious consumer brands to highly qualified and financially stable producer partners with the types of domestic and international quality certifications and capability uniquely found at NAI.  Our inventories increased in the period as these materials will be necessary to meet expanded demand in our system.”

NAI, headquartered in Carlsbad, California, is a leading formulator, manufacturer and marketer of nutritional supplements and provides strategic partnering services to its customers.  Our comprehensive partnership approach offers a wide range of innovative nutritional products and services to our clients including: scientific research, clinical studies, proprietary ingredients, customer-specific nutritional product formulation, product testing and evaluation, marketing management and support, packaging and delivery system design, regulatory review and international product registration assistance. For more information about NAI, please see our website at http://nai-online.com.

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934 that are not historical facts and information.  These statements represent our intentions, expectations and beliefs concerning future events, including, among other things, our future revenue profits and financial condition, our ability to maintain our patents, generate revenues from the commercialization of our patents and trademarks, secure compliance with our intellectual property rights, and develop, maintain or increase sales to new and existing customers, as well as future economic conditions and the impact of such conditions on our business. We wish to caution readers these statements involve risks and uncertainties that could cause actual results and outcomes for future periods to differ materially from any forward-looking statement or views expressed herein.  NAI’s financial performance and the forward-looking statements contained herein are further qualified by other risks including those set forth from time to time in the documents filed by us with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K.

CONTACT – Michael Fortin, Chief Financial Officer, Natural Alternatives International, Inc., at 760-736-7700 or [email protected].

Web site: http://nai-online.com

CARLSBAD, Calif., Feb. 13, 2018 /PRNewswire/ — Natural Alternatives International, Inc. (“NAI”) (Nasdaq: NAII), a leading formulator, manufacturer and marketer of customized nutritional supplements, today announced a net loss of $1.3 million, or $0.20 per diluted share, on net sales of $33.3 million for the quarter ended December 31, 2017.  Quarterly results were unfavorably impacted by one-time tax expense amounts recorded in connection with the Tax Cuts and Jobs Act (the “Act”) that was enacted on December 22, 2017.  These one-time charges totaled $3.3 million, or approximately $0.49 per diluted share.  Excluding these one-time tax items, our adjusted net income during the second quarter of fiscal 2018 was $1.9 million, or $0.29 per diluted share.

Net sales during the three months ended December 31, 2017 increased $2.8 million, or 9.1%, from $30.6 million recorded in the comparable prior year period.  For the quarter ended December 31, 2017, private label contract manufacturing sales increased $5.5 million, or 23.0%, from the comparable quarter last year.  Our second quarter fiscal 2018 contract manufacturing sales increased primarily due to an increase in sales to our largest customer to historical levels and shipment of new products under our previously announced expanded relationship with the same customer.  Additionally, we experienced increased sales of current products to other existing customers partially offset by the timing and shipment of orders of current products to existing customers and discontinued customer relationships.

CarnoSyn® beta-alanine royalty, licensing and raw material sales revenue decreased 40.6% to $4.0 million during the second quarter of fiscal 2018 as compared to $6.7 million for the second quarter of fiscal 2017.  The decrease in beta-alanine revenue was primarily due to decreased material shipments as a result of market and seasonal factors and lower average material sales prices.  During the quarter ended December 31, 2017, the sports nutrition retail market conditions declined most notably in the standard “brick and mortar” sales channels as products transitioned to higher levels of internet based sales.  This transition resulted in excess inventory in certain channels and delayed the re-order rates for many of our customer brands.  To date in our third quarter ending March 31, 2018, our re-order rates have improved for many of our customer brands suggesting improved sports nutrition retail market conditions. Additionally, our SR CarnoSyn® raw material sales have continued to increase during the current quarter as more brands adopted product offerings using this effective delivery system. There can be no assurance our sales and marketing efforts or the recent apparent improvement in retail market conditions will reverse or decelerate potential future declines of our CarnoSyn® beta-alanine sales.

Net sales during the six months ended December 31, 2017 decreased $3.2 million to $61.4 million, or 5.0%, from $64.6 million recorded in the comparable prior year period.  For the six months ended December 31, 2017, private label contract manufacturing sales increased $0.3 million, or 1.0%, from the comparable period last year.  The increase in private label contract manufacturing sales included an 18.8% decrease during our first quarter, primarily from reduced orders from our largest customer for specific products associated with an inventory reduction program, that was offset by a 23.0% increase in sales during our second quarter primarily due to the increase in sales to our largest customer to historical levels and shipment of new products under our previously announced expanded relationship.

CarnoSyn® beta-alanine royalty, licensing and raw material sales revenue decreased 26.5% to $9.8 million during the first half of fiscal 2018 as compared to $13.4 million for the comparable prior year period.  The decrease in CarnoSyn® beta-alanine revenue was primarily due to decreased material shipments as a result of market and seasonal factors, and lower average material sales prices.

Net income for the first six months of fiscal 2018 was $0.1 million, or $0.02 per diluted share, compared to net income of $5.0 million, or $0.74 per diluted share, in the comparable prior year period.  Our year-to-date fiscal 2018 results were unfavorably impacted by one-time tax expense amounts recorded in connection with the Act.  These one-time charges totaled $3.3 million, or approximately $0.48 per diluted share.  Excluding these one-time tax items, our adjusted net income during the first half of fiscal 2018 was $3.4 million, or $0.50 per diluted share.  This decrease was primarily attributable to decreased sales from our patent and trademark licensing segment.

As of December 31, 2017, NAI had cash of $28.8 million and working capital of $43.5 million compared to $27.8 million and $41.4 million, respectively, as of June 30, 2017.  As of December 31, 2017, we had $10.0 million available under our line of credit agreements.

Mark A. Le Doux, Chairman and Chief Executive Officer stated, “While our net income for our second fiscal quarter of 2018 was negatively impacted by one-time expenses as a result of the implementation of the new tax legislation, I am pleased with our pre-tax earnings results and our sequential quarterly profit trend. We believe the decline in our global effective tax rate will have a positive impact on our profitability and cash flow in the future.  Our second quarter of fiscal 2018 also reflected the positive impact of increased and new deliveries from our expanded relationship with our largest customer.

“While brick and mortar locations have suffered significant disruptions due to internet sales co-opting in-person transactions, we are seeing re-order rates of CarnoSyn® trending towards historical levels along with more market adoption of SR CarnoSyn®.  Furthermore, our contract manufacturing expansion in the second quarter bodes well for the balance of this fiscal year.”

NAI, headquartered in Carlsbad, California, is a leading formulator, manufacturer and marketer of nutritional supplements and provides strategic partnering services to its customers.  Our comprehensive partnership approach offers a wide range of innovative nutritional products and services to our clients including: scientific research, clinical studies, proprietary ingredients, customer-specific nutritional product formulation, product testing and evaluation, marketing management and support, packaging and delivery system design, regulatory review and international product registration assistance. For more information about NAI, please see our website at http://nai-online.com.

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934 that are not historical facts and information.  These statements represent our intentions, expectations and beliefs concerning future events, including, among other things, our future revenue profits and financial condition, our ability to maintain our patents, generate revenues from the commercialization of our patents and trademarks, secure compliance with our intellectual property rights, and develop, maintain or increase sales to new and existing customers, as well as future economic conditions and the impact of such conditions on our business. We wish to caution readers these statements involve risks and uncertainties that could cause actual results and outcomes for future periods to differ materially from any forward-looking statement or views expressed herein.  NAI’s financial performance and the forward-looking statements contained herein are further qualified by other risks including those set forth from time to time in the documents filed by us with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K.

CONTACT – Michael Fortin, Chief Financial Officer, Natural Alternatives International, Inc., at 760-736-7700 or [email protected].

Web site: http://nai-online.com

 

January 17, 2018 CARLSBAD, CA

 

CARLSBAD, Calif., Jan. 17, 2018 /PRNewswire/ — Natural Alternatives International, Inc. (“NAI”) (NASDAQ: NAII), a leading formulator, manufacturer and marketer of customized nutritional supplements, announced today that the U.S. Patent and Trademark Office has issued a Notice of Allowance for NAI instant release beta-alanine patent application entitled “Methods And Compositions For Increasing The Anaerobic Working Capacity In Tissues.”  The newly allowed application becomes part of NAI’s global patent estate covering its CarnoSyn® instant release beta-alanine product.

Mark A. LeDoux, NAI’s CEO and Chairman of the Board, said that “this patent provides athletes with important guidance related to increasing muscle carnosine levels and achieving a maintenance level from which the athlete can build as desired over time with varying amounts of beta-alanine supplementation.”  As another important piece to NAI’s global strategy for providing performance increases well beyond those achievable through normal diets, this patent “will insure that athletes have the appropriate information and abilities to adequately reach their competitive goals,” said Mr. LeDoux.  NAI’s allowed claims are directed to methods of delaying muscle fatigue through supplementation with instant release beta-alanine in times and amounts to increase muscle carnosine levels beyond that obtainable through diet alone.  The claimed methods allow for a loading phase and a maintenance phase of supplementation, and allows for further loading after achieving and maintaining a desired level of muscle carnosine.

NAI, headquartered in Carlsbad, California, is a leading formulator, manufacturer and marketer of nutritional supplements and provides strategic partnering services to its customers. NAI’s comprehensive partnership approach offers a wide range of innovative nutritional products and services to NAI’s clients including: scientific research, clinical studies, proprietary ingredients, customer-specific nutritional product formulation, product testing and evaluation, marketing management and support, packaging and delivery system design, regulatory review and international product registration assistance. For more information about NAI, please see its website at http://nai-online.com.

This press release contains forward-looking statements within the meaning of applicable securities laws that are not historical facts and information. These statements represent our intentions, expectations and beliefs concerning future events, including, among other things, our expectations and beliefs with respect to our future financial and operating results, the outcome of pending litigation, the continued validity of our patents, and our ability to successfully develop, license and enforce our intellectual property rights. We wish to caution readers these statements involve risks and uncertainties that could cause actual results and outcomes for future periods to differ materially from any forward-looking statement or views expressed herein. NAI’s financial performance and the forward-looking statements contained herein are further qualified by other risks including those set forth from time to time in the documents filed by us with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and Quarterly Report on Form 10-Q.

CONTACT: Kenneth Wolf, President, Natural Alternatives International, Inc., at 760-736-7700 or [email protected].

WEBSITE:  http://nai-online.com and http://www.carnosyn.com